Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment

This study has been terminated.

( Study terminated by Principal Investigator; no patients completed study. )

Study NCT00409331 Information provided by M.D. Anderson Cancer Center

First Received on December 7, 2006. Last Updated on December 11, 2009 History of Changes

Results First Received: December 11, 2009

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Head and Neck Cancer
Interventions:	Drug: Amifostine Procedure: Intensity- Modulated Radiation Therapy

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 06/12/07 through 01/14/08. All participants recruited at UT MD Anderson Cancer Center.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Study terminated due to slow accrual and change in sponsor. Three patients registered, two removed prior to study beginning as not eligible.

Reporting Groups

	Description
IMRT + Amifostine	Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.

Participant Flow: Overall Study

Baseline Characteristics

Reporting Groups

	Description
IMRT + Amifostine	Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.

Baseline Measures

	IMRT + Amifostine
Number of Participants [units: participants]	1
Age [units: years] Median ( Full Range )	48 ( 48 to 48 )
Gender [units: participants]
Female	0
Male	1
Region of Enrollment [units: participants]
United States	1

Outcome Measures

1. Primary:

12-month Clinically Relevant Salivary Flow (CRSF) [ Time Frame: 12 months ]

Show Outcome Measure 1

Serious Adverse Events

Other Adverse Events

More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Mark Chambers, DMD / Associate Professor
Organization: UT MD Anderson Cancer Center
phone: 713-745-2672

No publications provided

Responsible Party:	Mark Chambers, DMD/Assoc. Professor, U.T. M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00409331 History of Changes
Other Study ID Numbers:	2006-0234
Study First Received:	December 7, 2006
Results First Received:	December 11, 2009
Last Updated:	December 11, 2009
Health Authority:	United States: Food and Drug Administration